» Articles » PMID: 8759937

Mechanism and Computer Simulation of Immune Complex Formation, Opsonization, and Clearance

Overview
Journal J Lab Clin Med
Publisher Elsevier
Date 1996 Jul 1
PMID 8759937
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

A computer simulation of immune complex formation, opsonization, and clearance has been developed (ICMODEL) that uses equations describing the kinetics of known immunologic processes and an additional pathologic process of immune complex-mediated tissue damage and antigen production. ICMODEL was used to (1) compare simulated with reported immune response kinetics, (2) evaluate the relative stability of the immune system described by the simulation, and (3) determine the conditions required to produce high immune complex levels as found in patients with immune complex-mediated disease. ICMODEL simulated primary and secondary immune responses as well as short- and long-term immunity. ICMODEL also depicted a relatively stable immune response system. Under certain conditions, however, the system could be perturbed, resulting in an unstable response. For example, when the rate constant regulating Fc gamma-mediated phagocytosis was decreased and the rate constant regulating immune complex-mediated tissue damage/antigen production was increased, immune complex concentrations oscillated with time and increased exponentially. These data suggest that ICMODEL can be used to define the specific parameters that, when perturbed, will give rise to increased immune complex concentrations. As such, this model has direct implications for studies of immune complex-mediated disease in human patients.

Citing Articles

Mathematical modeling in autoimmune diseases: from theory to clinical application.

Ugolkov Y, Nikitich A, Leon C, Helmlinger G, Peskov K, Sokolov V Front Immunol. 2024; 15:1371620.

PMID: 38550585 PMC: 10973044. DOI: 10.3389/fimmu.2024.1371620.


Spatiotemporal dynamics of complement C5a production within bacterial extracellular polymeric substance.

Conrad E, Hsu Y, Bortz D, Younger J J Innate Immun. 2013; 5(2):114-23.

PMID: 23328643 PMC: 4096239. DOI: 10.1159/000345705.


Investigating the role of T-cell avidity and killing efficacy in relation to type 1 diabetes prediction.

Khadra A, Pietropaolo M, Nepom G, Sherman A PLoS One. 2011; 6(5):e14796.

PMID: 21573001 PMC: 3091860. DOI: 10.1371/journal.pone.0014796.


Antibodies as drug carriers III: design of oligonucleotides with enhanced binding affinity for immunoglobulin G.

Palma E, Klapper D, Cho M Pharm Res. 2005; 22(1):122-7.

PMID: 15771238 DOI: 10.1007/s11095-004-9017-z.


Anti-drug antibodies as drug carriers. I. For small molecules.

Rehlaender B, Cho M Pharm Res. 2001; 18(6):745-52.

PMID: 11474777 DOI: 10.1023/a:1011072009408.